Drug conjugates

Details Drug conjugates Drug conjugates

2007-10-16

2007-10-16

Anderson, Rebecca (Department: 1626)

Organic compounds -- part of the class 532-570 series

Organic compounds

Heterocyclic carbon compounds containing a hetero ring...

C548S542000, C562S432000

Reexamination Certificate

active

11053655

ABSTRACT:
A compound having the formula Y-A-Z, wherein:A is a 5, 6, or 7 member ring that is monocyclic or is fused to 1 to 3 additional 4 to 8 member rings; wherein ring A and, independently, the fused additional rings are carbocyclic or heterocyclic, and saturated or unsaturated, wherein unsaturated rings are aromatic or non-aromatic; wherein Y and Z are substituents at adjacent positions on ring A;Y represents:Z represents:X and E represent O, S, or NRaor NRb; each of a, b, c, d, e and f independently represents 0 or 1; a+c equals 0, 1, or 2; b+d equals 0, 1, or 2; a+b+c+d+e+f equals 1, 2, or 3; provided that when f is 1, then d is 1, and when d is 0, then f is 0; and when both e and b are 0, then neither R1nor R2is chloro or bromo; v represents 0 or 1, provided that when v is 0, then J is hydrogen, a metal ion, or a quaternary ammonium ion; and X is O and G is H;either G is hydrogen, a metal ion, a quaternary ammonium ion, lower alkyl, or comprised of a pharmaceutically active chemical compound or the precursor thereof; or X-G represents a carbonyl-activating group;J is lower alkyl, aryl, heteroaryl, omega-hydroxycarbonyl-(lower alkyl), omega-(lower alkoxy)carbonyl-(lower alkyl), omega-(X-G)-carbonyl-(lower alkyl) group, or comprised of a specific binding agent; and Ra, Rb, R1, R2, R3, R4are as defined in the specification.

REFERENCES:
patent: 3324140 (1967-06-01), Schorre et al.
patent: 3458563 (1969-07-01), Cragoe, Jr.
patent: 3600437 (1971-08-01), Marshall
patent: 4049665 (1977-09-01), Douglass
patent: 4258193 (1981-03-01), Fujii et al.
patent: 4324793 (1982-04-01), Hagen et al.
patent: 4493802 (1985-01-01), Jaedicke et al.
patent: 4505917 (1985-03-01), Menon et al.
patent: 4880935 (1989-11-01), Thorpe
patent: 4902826 (1990-02-01), Bauer et al.
patent: 5002967 (1991-03-01), Mueller et al.
patent: 5124441 (1992-06-01), Carlsson et al.
patent: 5137877 (1992-08-01), Kaneko et al.
patent: 5274184 (1993-12-01), Nagl et al.
patent: 5932731 (1999-08-01), Goda et al.
patent: 5936092 (1999-08-01), Shen et al.
patent: 6008321 (1999-12-01), Li et al.
patent: 6313150 (2001-11-01), Ohtsuka et al.
Block et al., Antithrombotic Organosulfur Compounds from Garlic: Structural, Mechanistic, and Synthetic Studies, J. Am. Chem. Soc., vol. 108, pp. 7045-7055 (1986).
Bressler et al., “Identification of disulfides from the biodegradation of dibenzothiophene,” Applied and Environmental Microbiology, vol. 67(11), pp. 5084-5093 (2001).
Y. Ueda, “Novel Water Soluble Phosphate Prodrugs of Taxol® Possessing in Vivo Antitumor Activity”,Bioorganic&Medicinal Chemistry Letters, vol. 3, No. 8, pp. 1761-1766 (1993).
I. Ojima et al., “Syntheses and Structure—Activity Relationships of the Second-Generation Antitumor Taxoids: Exceptional Activity against Drug-Resistant Cancer Cells”,J. Med. Chem., vol. 39, No. 20, pp. 3889-3896 (1996).
M.P. Dillon et al. “Application of the ‘Trimethyl Lock’ to Ganciclovir, a Pro-Prodrug with Increased Oral Bioavailability”,Bioorganic&Medicinal Chemistry Letters, vol. 6, No. 14, pp. 1653-1656 (1996).
B. Wang et al., “Synthesis of a Novel Esterase-Sensitive Cyclic Prodrug System for Peptides that Utilizes a ‘Trimethyl Lock’-Facilitated Lactonization Reaction”,J. Org. Chem., vol. 62, No. 5, pp. 1363-1367 (1997).
I. Ojima et al., “Synthesis and Structure—Activity Relationships of New Second-Generation Taxoids”,Bioorg. Med. Chem. Lett., vol. 9, pp. 3423-3428 (1999).
R.B. Greenwald et al., “Drug Delivery Systems Based on Trimethyl Lock Lactonization: Poly(ethylene glycol) Prodrugs of Amino-Containing Compounds”,J. Med. Chem., vol. 43, No. 3, pp. 475-487 (2000).
K. Achilles, “Coumarin Derivatives as Protease-Sensitive Prodrugs”,Arch. Pharm. Pharm. Med. Chem., vol. 334, pp. 209-215 (2001).
M.R. Vredenburg et al., “Effects of Orally Active Taxanes on P-Glycoprotein Modulation and Colon and Breast Carcinoma Drug Resistance”,Journal of the National Cancer Institute, vol. 93, No. 16, pp. 1234-1245 (2001).

Affiliated with

Also associated with

Rating

Drug conjugates does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Drug conjugates, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Drug conjugates will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3860685